Previous 10 | Next 10 |
Saol Therapeutics is collaborating with OPKO Health's (NASDAQ:OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) who may be eligible to participate in a Phase 3 clinical trial. The companies said ...
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease Program Supports Access to A Pivotal Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency (DCA/PDCD trial; NCT02616484) PR Newswire ROSWELL, G...
As the week came to an end, a clutch of investors were ditching Opko Health (NASDAQ: OPK) following the company's Q4 earnings release. Shares of the healthcare diagnostic specialist fell marginally on the day as a result. In the release, published after market hours on Thursday,...
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Opko Health (OPK) Q4 2021 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2021 Earnings Conference Call February 24, 2022 04:30 PM ET Company Participants Yvonne Briggs - Investor Relations Phillip Frost - Chairman & Chief Executive Officer Steve Rubin - Executive Vice President Jon Cohen - Managing Director, Executive Chairman of Bio...
OPKO Health (NASDAQ:OPK), a healthcare company focused on diagnostics and pharmaceuticals, is trading ~10% lower in the post-market Thursday after indicating a mixed performance with its Q4 2021 results amid falling COVID-19 testing volumes. Revenue for the quarter dropped ~19% YoY ...
OPKO Health press release (NASDAQ:OPK): Q4 GAAP EPS of -$0.11 misses by $0.09. Revenue of $401.3M (-18.9% Y/Y) beats by $84.04M. Revenue from services in the fourth quarter of 2021 were to $362.8M compared to $457.9M in the prior-year period. Revenue from products in the fourth quarter of 202...
MIAMI, Feb. 24, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2021. Business Highlights Business highlights for the fourth quarter of 2021 and subsequent weeks include the ...
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022. OPKO’s senior management will provid...
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and ad...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...